^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Molecular characteristics of BRAF mutated non-small cell lung cancer and therapeutic outcomes: Multi-institution study.

Published date:
05/19/2021
Excerpt:
BRAF mutant NSCLC is associated with high PD-L1 expression and responses to both checkpoint inhibitors and BRAF inhibitor combinations. Treatment with immunotherapy appears to have a superior toxicity profile and prolonged disease control in both BRAF V600E and non-V600E mutant NSCLC and is an effective first-line strategy.
DOI:
10.1200/JCO.2021.39.15_suppl.e21029